CDMO Services
Thanks to its two veterinary and human pharmacy plants, LABIANA has unique operational flexibility and a great capacity to offer high quality contract manufacturing services to all companies in the sector, regardless of batch size required.
Animal health products
More than 60 years’ experience as a manufacturer, complying with very high-quality standards are reflected in a wide product portfolio to help livestock farms achieve the highest levels of productivity and efficiency.
Human medicine products
In the pharmaceutical sector, LABIANA is a benchmark in contract manufacturing and sterile forms for third parties. Moreover, in recent years it has become a leading manufacturer and distributor of Fosfomycin Trometamol under its own brand: Fosfomicina Labiana.
Company
LABIANA has a long history in the pharmaceutical-veterinary sector. In continuous evolution since its foundation in 1958 as a company producing nutritional products for animal health, later becoming a subsidiary of the BASF Germany group for more than 20 years and then evolving into a modern and competitive company that currently offers a wide range of products and services.
Veterinarski Zavod Subotica was founded in 1921, as part of the former Yugoslavia Patria Group. In 2019 has been 100% acquired by Labiana and, nowadays, is focusing on the development and manufacturing of biologicals (viral, bacterial and autogenous vaccines), chemo-pharmaceutical products (sterile solutions aseptically filled and terminal sterilized, non-sterile liquids and solids), dermocosmetics, dietary supplements and biocides.
Zoleant Pharmaceuticals International was established in 2016 for the development and global marketing & sales of niche alternative brand medicines that have been in the market for many years. This dedication has ensured access to affordable, high quality medicines for all. The commitment and knowledge of its professionals not only has allowed for Zoleant Pharmaceuticals to create generic medicines, but innovatively new feed additives.
News
Labiana closed the 2024 fiscal year with revenues of €66.26 million, representing a 13.3% increase compared to the previous year.
Labiana, the pharmaceutical laboratory specialized in animal and human health listed on BME Growth, has added Lexylan, a new antibiotic classified as Category C in its prescription guidelines, to its product portfolio.
Labiana, the pharmaceutical laboratory specialized in both animal and human health listed on BME Growth, is expanding its business in the human health sector with the launch of a product line dedicated entirely to the well-being and care of women.
EUROPEAN REGIONAL DEVELOPMENT FUND
Labiana Pharmaceuticals S.L. within the framework of the ICEX Next program, aimed to start off Export activities, has had the support of ICEX and the co-financing of the European ERDF fund. The purpose of this funding is to contribute to the international development of the company and its business setting.
A way to make Europe
